DreaMed’s Automated Insulin Delivery Technology Is Featured in Medtronic’s New System Bringing Its Vision of Helping People With Type 1 Diabetes to Life
Summary
PETAH TIKVA, Israel--(BUSINESS WIRE)--DreaMed Diabetes is announcing the use of its Artificial Pancreas algorithm in Medtronic’s new CE Marked MiniMed 780G Advanced Hybrid Closed Loop system. Involved in the development of the technology are DreaMed founders Prof. Moshe Phillip, Dr. Revital Nimri, Shahar Miller, Eli Grunberg, Aviel Fogel, Ido Muller, Prof Thomas Danne, Prof. Tadej Battelino, Prof. Olga Kordonouri, Dr. Natasa Bratina and Eran Atlas. We are proud to be a part of the latest update in the Medtronic MiniMed line of products, optimizing the insulin delivery of each user," says DreaMed Diabetes CEO and co-founder Eran Atlas. Our current focus is on our DreaMed Advisor platform which is already being adopted by leading diabetes centers in the U.S. We are thrilled that our first professional life mission is live and will have a positive impact on many people around the world. As we expected, the automatic boluses (which are unique on this system in the ability to be delivered every 5 minutes) are a powerful tool to all, but especially important for the adolescent age group.
Classifications
AskAI Classifications
LabelsLinked Companies
